Among the emerging therapeutic options, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential in reducing adverse events in patients with type 2 diabetes [235] and obesity with preserved ejection fraction [236]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.